HBP Share Price

Open 1.30 Change Price %
High 1.30 1 Day 0.00 0.00
Low 1.30 1 Week 0.00 0.00
Close 1.30 1 Month -0.03 -2.26
Volume 1200 1 Year -0.64 -32.99
52 Week High 2.25
52 Week Low 1.20
HBP Important Levels
Resistance 2 1.30
Resistance 1 1.30
Pivot 1.30
Support 1 1.30
Support 2 1.30
TSE Canada Most Active Stocks
LUN 7.39 -0.81%
LUN 7.39 -0.81%
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 3.70 -4.15%
BTO 3.78 -4.79%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
XRC 2.41 56.49%
PWC 0.10 25.00%
PWC 0.10 25.00%
DNT 0.11 22.22%
IMP 0.07 16.67%
IMP 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
MMM 0.19 -13.64%
MMM 0.19 -13.64%
MMM 0.19 -13.64%
MMM 0.19 -13.64%
RN 0.15 -11.76%
RN 0.15 -11.76%
HCG 25.06 -9.60%
HCG 25.06 -9.60%
HCG 25.06 -9.60%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 4
As on 28th Mar 2017 HBP Share Price closed @ 1.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.77 & Sell for SHORT-TERM with Stoploss of 1.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for March
1st Target up-side 1.43
2nd Target up-side 1.5
3rd Target up-side 1.57
1st Target down-side 1.23
2nd Target down-side 1.16
3rd Target down-side 1.09
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.